Stock FDMT 4D MOLECULAR THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages 4D Molecular Therapeutics, Inc.

Equities

FDMT

US35104E1001

Market Closed - Nasdaq
Other stock markets
 21:30:01 03/05/2024 BST 		5-day change 1st Jan Change
26.38 USD 0.00% Intraday chart for 4D Molecular Therapeutics, Inc. +13.46% +30.21%
04-15 Barclays Starts 4D Molecular Therapeutics With Overweight Rating, $45 Price Target MT
04-15 RBC Raises Price Target on 4D Molecular Therapeutics to $40 From $35, Keeps Outperform Rating, Speculative Risk Qualifier MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
4D Molecular Therapeutics Insider Sold Shares Worth $259,102, According to a Recent SEC Filing
4D Molecular Reports Regulatory Updates on 4D-710 For Cystic Fibrosis
4Dmt Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
4D Molecular Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
4D Molecular Therapeutics, Inc. Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium? 2024
4d Molecular Therapeutics Insider Sold Shares Worth $737,788, According to a Recent SEC Filing
4D Molecular Therapeutics Launches $250 Million Stock Offering
4D Molecular Therapeutics Shares Surge on Positive Data From Phase 2 Study of Wet AMD Drug Candidate
Top Midday Gainers
4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes'
Powell Comments Dampen Near-Term Rate Cut Hopes, Stifling US Equity Futures Pre-Bell
Top Premarket Gainers
4D Molecular Therapeutics Presents Positive Interim Data from Randomized Phase 2 Prism Clinical Trial of Intravitreal 4D-150
4D Molecular Therapeutics' Treatment Candidate for Cystic Fibrosis Gets FDA Rare Pediatric Disease Designation
4D Molecular Therapeutics Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease
4D Molecular Therapeutics, Inc. Announces Management Changes
4D Molecular Therapeutics Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates
4D Molecular Therapeutics and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases
4D Molecular Therapeutics, Arbor Biotechnologies Form Central Nervous System Disease Partnership
4D Molecular Therapeutics Shares Rise as Wet AMD Treatment Candidate Gets FDA's RMAT Designation
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FDMT Stock
  4. News 4D Molecular Therapeutics, Inc.
  5. Other languages